Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study

Figures & data

Figure 1. Study flow chart. Summary clinical sample characteristics by study group.

Table 1. Systolic and diastolic blood pressure at baseline at baseline and at weeks 6 and 12 after study enrolment and implementation of the new therapeutic measures with one of 3 fixed combination ARB/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day).^a

		v0		v6		v12
		SBP	DBP	SBP	DBP	SBP	DBP
GI - Previous Monotherapy	Mean	154,8	89,4	136,2	79,5	130,8	77,3
	SD	10,5	9,8	12,3	8,8	10,4	8,8
GII - Previous Hydrochlorothiazide	Mean	156,2	90,0	137,7	80,6	132,3	78,5
	SD	10,2	8,5	11,6	9,2	9,9	8,5
GIII - Previous No Medication	Mean	163,6	93,0	141,5	81,4	133,3	77,5
	SD	14,1	9,4	14,5	9,6	12,2	8,9
Total	Mean	159,0	91,1	138,8	80,5	132,1	77,5
	SD	13,0	9,6	13,5	9,2	11,3	8,8

^a Descriptive statistics including means and standard deviation estimates. Inferential statistics, such as p-values from the Repeated Measures Multivariate Analysis of Covariance (MANCOVA), are provided in Figure 2.

Anti-hypertension (anti-HTN) therapy before study enrolment: Anti-HTN monotherapies (Group I, GI); combinations with hydrochlorothiazide (HCTZ) (Group II, GII); not receiving medication at all (Group III, GIII).

Assessment at visit (v) v0 (baseline), v6 (week 6) and v12 (week 12) after study enrolment.

SBP- Systolic Blood Pressure in mm Hg; DBP - Diastolic Blood Pressure in mm Hg.

Table 2. Number (N) and percentage (%) of study participants with uncontrolled and controlled hypertension (HTN) at baseline and at weeks 6 and 12 after study enrolment and implementation of the new therapeutic measures with one of 3 fixed combination candesartan/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day).

		v0		v6		v12
		Uncontrolled	Controlled	Uncontrolled	Controlled	Uncontrolled	Controlled
GI Previous Monotherapy	N	328	4	105	227	45	287
	%	98,8%	1,2%	31,6%	68,4%	13,6%	86,4%
GII Previous Hydrochlorothiazide	N	75	2	26	51	11	66
	%	97,4%	2,6%	33,8%	66,2%	14,3%	85,7%
GIII Previous No Medication	N	343	0	161	182	82	261
	%	100,0%	0,0%	46,9%	53,1%	23,9%	76,1%
Total	N	746	6	292	460	138	614
	%	99,2%	0,8%	38,8%	61,2%	18,4%	81,6%

Anti-hypertension (anti-HTN) before study enrolment: Anti-HTN monotherapies (Group I, GI); combinations with hydrochlorothiazide (HCTZ) (Group II, GII); not receiving medication at all (Group III, GIII).

Assessment at visit (v) v0 (baseline), v6 (week 6) and v12 (week 12) after study enrolment.

Figure 2. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) across time by sex and study group.